Press releases
- HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- HLS Therapeutics Announces Fiscal 2023 Financial Results
- HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
- HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 31.89m |
Free float | 31.73m |
P/E (TTM) | -- |
Market cap | 156.82m CAD |
EPS (TTM) | -1.17 CAD |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Apr 27 2023 |
Div pay-date | Jun 15 2023 |
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼